DelveInsight’s “Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted epidemiology as well as the Paroxysmal Nocturnal Hemoglobinuria market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Paroxysmal Nocturnal Hemoglobinuria market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Paroxysmal Nocturnal Hemoglobinuria Market Forecast
Some of the key facts of the Paroxysmal Nocturnal Hemoglobinuria Market Report:
-
The Paroxysmal Nocturnal Hemoglobinuria market size was valued approximately USD 11 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
-
In 2022, the collective cases of paroxysmal nocturnal hemoglobinuria (PNH) in the 7MM countries amounted to approximately 12,400, with expectations of a rise during the study duration. The United States contributed around 6,000 cases of PNH in 2022.
-
In 2022, approximately 2,500 cases of paroxysmal nocturnal hemoglobinuria (PNH) were reported in the United Kingdom.
-
In 2022, within the EU4, Germany recorded the highest incidence of paroxysmal nocturnal hemoglobinuria (PNH), totaling around 1,300 cases, while France followed with approximately 800 cases.
-
Regarding gender-specific prevalence of paroxysmal nocturnal hemoglobinuria (PNH) in 2022, females comprised approximately 3,100 cases, whereas males accounted for around 2,900 cases in the United States.
-
Key Paroxysmal Nocturnal Hemoglobinuria Companies: Alexion Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceuticals, Inc., Hoffmann-La Roche, Omeros Corporation, Novartis, Chengdu Suncadia Medicine Co., Ltd., Wuhan Createrna Science, Regeneron Pharma, Kira Pharma, NovelMed Therapeutics, Alexion Pharmaceuticals, Inc., Apellis Pharma, and others
-
Key Paroxysmal Nocturnal Hemoglobinuria Therapies: Eculizumab, BCX9930, Pegcetacoplan, Crovalimab, OMS906 study drug, HRS-5965 tablets, MY008211A tablets, Iptacopan, Pozelimab, KP104, NM8074, Danicopan, Pegcetacoplan, and others
-
The Paroxysmal Nocturnal Hemoglobinuria based on gender analyzed that the majority of cases of PNH are female as compared to male
-
The Paroxysmal Nocturnal Hemoglobinuria market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Paroxysmal Nocturnal Hemoglobinuria pipeline products will significantly revolutionize the Paroxysmal Nocturnal Hemoglobinuria market dynamics.
Paroxysmal Nocturnal Hemoglobinuria Overview
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and acquired hematologic disorder characterized by the abnormal breakdown of red blood cells (hemolysis), blood clots (thrombosis), and impaired bone marrow function. It is caused by a mutation in the PIGA gene, which leads to the deficiency of proteins that anchor certain cell surface proteins (such as CD55 and CD59) that protect red blood cells from destruction by the body's immune system.
Get a Free sample for the Paroxysmal Nocturnal Hemoglobinuria Market Report:
https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-market
Paroxysmal Nocturnal Hemoglobinuria Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Paroxysmal Nocturnal Hemoglobinuria Epidemiology Segmentation:
The Paroxysmal Nocturnal Hemoglobinuria market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
-
Total Prevalence of Paroxysmal Nocturnal Hemoglobinuria
-
Prevalent Cases of Paroxysmal Nocturnal Hemoglobinuria by severity
-
Gender-specific Prevalence of Paroxysmal Nocturnal Hemoglobinuria
-
Diagnosed Cases of Episodic and Chronic Paroxysmal Nocturnal Hemoglobinuria
Download the report to understand which factors are driving Paroxysmal Nocturnal Hemoglobinuria epidemiology trends @ Paroxysmal Nocturnal Hemoglobinuria Epidemiology Forecast
Paroxysmal Nocturnal Hemoglobinuria Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Paroxysmal Nocturnal Hemoglobinuria market or expected to get launched during the study period. The analysis covers Paroxysmal Nocturnal Hemoglobinuria market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Paroxysmal Nocturnal Hemoglobinuria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Paroxysmal Nocturnal Hemoglobinuria Therapies and Key Companies
-
Eculizumab: Alexion Pharmaceuticals
-
BCX9930: BioCryst Pharmaceuticals
-
Pegcetacoplan: Apellis Pharmaceuticals, Inc.
-
Crovalimab: Hoffmann-La Roche
-
OMS906 study drug: Omeros Corporation
-
HRS-5965 tablets: Chengdu Suncadia Medicine Co., Ltd.
-
MY008211A tablets: Wuhan Createrna Science
-
Iptacopan: Novartis
-
Pozelimab: Regeneron Pharma
-
KP104: Kira Pharma
-
NM8074: NovelMed Therapeutics
-
Danicopan: Alexion Pharmaceuticals, Inc.
-
Pegcetacoplan: Apellis Pharma
Discover more about therapies set to grab major Paroxysmal Nocturnal Hemoglobinuria market share @ Paroxysmal Nocturnal Hemoglobinuria Treatment Market
Paroxysmal Nocturnal Hemoglobinuria Market Strengths
-
Despite receiving treatment with a C5 inhibitor, patients may still experience continuous hemolysis, persistent chronic anemia, need for continued blood transfusions, fatigue, and poor health-related quality of life
-
The physicians are not generally aware of the broad spectrum of signs and symptoms of the disease, which are often similar to those of other diseases, and vary from one patient to another
Paroxysmal Nocturnal Hemoglobinuria Market Opportunities
-
The C5 targeting monoclonal antibody eculizumab has changed the natural history of PNH in the last 10 years. This is a great opportunity to develop new biomarkers to assess thrombotic risk in PNH patients
-
There is a potential for companies to price their drugs at a premium price if their therapies provide an edge over the current therapies
Scope of the Paroxysmal Nocturnal Hemoglobinuria Market Report
-
Study Period: 2019–2032
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Paroxysmal Nocturnal Hemoglobinuria Companies: Alexion Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceuticals, Inc., Hoffmann-La Roche, Omeros Corporation, Novartis, Chengdu Suncadia Medicine Co., Ltd., Wuhan Createrna Science, Regeneron Pharma, Kira Pharma, NovelMed Therapeutics, Alexion Pharmaceuticals, Inc., Apellis Pharma, and others
-
Key Paroxysmal Nocturnal Hemoglobinuria Therapies: Eculizumab, BCX9930, Pegcetacoplan, Crovalimab, OMS906 study drug, HRS-5965 tablets, MY008211A tablets, Iptacopan, Pozelimab, KP104, NM8074, Danicopan, Pegcetacoplan, and others
-
Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment: Paroxysmal Nocturnal Hemoglobinuria current marketed and Paroxysmal Nocturnal Hemoglobinuria emerging therapies
-
Paroxysmal Nocturnal Hemoglobinuria Market Dynamics: Paroxysmal Nocturnal Hemoglobinuria market drivers and Paroxysmal Nocturnal Hemoglobinuria market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Paroxysmal Nocturnal Hemoglobinuria Unmet Needs, KOL’s views, Analyst’s views, Paroxysmal Nocturnal Hemoglobinuria Market Access and Reimbursement
To know more about Paroxysmal Nocturnal Hemoglobinuria companies working in the treatment market, visit @ Paroxysmal Nocturnal Hemoglobinuria Clinical Trials and Therapeutic Assessment
Table of Contents
1. Paroxysmal Nocturnal Hemoglobinuria Market Report Introduction
2. Executive Summary for Paroxysmal Nocturnal Hemoglobinuria
3. SWOT analysis of Paroxysmal Nocturnal Hemoglobinuria
4. Paroxysmal Nocturnal Hemoglobinuria Patient Share (%) Overview at a Glance
5. Paroxysmal Nocturnal Hemoglobinuria Market Overview at a Glance
6. Paroxysmal Nocturnal Hemoglobinuria Disease Background and Overview
7. Paroxysmal Nocturnal Hemoglobinuria Epidemiology and Patient Population
8. Country-Specific Patient Population of Paroxysmal Nocturnal Hemoglobinuria
9. Paroxysmal Nocturnal Hemoglobinuria Current Treatment and Medical Practices
10. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs
11. Paroxysmal Nocturnal Hemoglobinuria Emerging Therapies
12. Paroxysmal Nocturnal Hemoglobinuria Market Outlook
13. Country-Wise Paroxysmal Nocturnal Hemoglobinuria Market Analysis (2019–2032)
14. Paroxysmal Nocturnal Hemoglobinuria Market Access and Reimbursement of Therapies
15. Paroxysmal Nocturnal Hemoglobinuria Market Drivers
16. Paroxysmal Nocturnal Hemoglobinuria Market Barriers
17. Paroxysmal Nocturnal Hemoglobinuria Appendix
18. Paroxysmal Nocturnal Hemoglobinuria Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
